LLY vs ZBH
By Alex · Tickerpine
Eli Lilly and Company vs Zimmer Biomet Holdings, Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | ZBH |
|---|---|---|
| Price | $1,183.46 | $91.04 |
| Market cap | $1.06T | $17.36B |
| P/E ratio | 39.7 | 22.1 |
| ROE | 102.29% | 6.41% |
| Profit margin | 33.53% | 9.48% |
| Revenue growth | 47.70% | 4.80% |
| Dividend yield | 0.58% | 1.05% |
| Beta | 0.50 | 0.47 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs ZBH in plain English
- LLY is the bigger company — about 60.8× the market cap of ZBH.
- ZBH is cheaper on earnings (P/E 22.1 vs 39.7).
- LLY earns a higher return on equity (102% vs 6%).
- LLY is growing revenue faster (48% vs 5%).
- ZBH has the higher dividend yield (1.05% vs 0.58%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
ZBH return calculator
See what $1,000 in Zimmer Biomet Holdings, Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.